The diagnosis, staging, and prognosis of chronic kidney disease (CKD) depend on the measurement of the glomerular filtration rate (GFR). A low GFR is associated with an increased risk of cardiovascular disease and early mortality. Current guidelines for CKD recommend using cystatin C as a supplementary test to ensure accurate estimation of eGFR. In the present study, we aimed to compare the efficacy of cystatin C-based eGFR with serum creatinine-based eGFR before and after contrast-enhanced intravenous urography (IVU). The present study is a retrospective observational study conducted in 51 patients aged 10 to 70 years. Of these patients, 21 were female and 30 were male, all of whom had kidney diseases and attended the hospital from January 2021 to January 2022. In this study, we evaluated the serum levels of urea, creatinine, and cystatin C before and after administering iodine solution to each participant. The study found no significant changes in blood urea and serum creatinine levels before and after administering the iodine solution. However, there was a significant variation in the levels of cystatin C. The levels of eGFR-dependent creatinine did not differ significantly, but there were significant changes in eGFR-dependent cystatin levels. Our findings suggest that cystatin C is a more accurate method of monitoring kidney function compared to creatinine levels. Additionally, cystatin C appears to be a more reliable marker of renal failure than serum creatinine and urea.